使用里瓦罗克萨班治疗近道深静脉血栓症的3个月单药疗法的影响
Kazuhiro Shimizu1, Takeshi Sasaki2, Shunsuke Todani1
1Department of Internal Medicine, Toho University Sakura Medical Center Sakura Japan.
Circulation reports
|June 11, 2024
概括
里瓦洛克萨班提供有效的深静脉血栓塞 (DVT) 治疗,在三个月内,与传统抗凝剂相比,显示出较大的血栓回归. 这项研究突出了里瓦洛克萨班的作用.
科学领域:
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
- 医疗成像医学成像
背景情况:
- 直接口服抗凝剂,如利瓦洛克萨班,由于治疗方便,越来越多地用于深静脉血栓症 (DVT).
- 对于对DVT治疗后三个月的凝块负担评估存在有限的数据.
- 定量超声波血栓形成 (QUT) 评分是评估凝块体积的一种方法.
研究的目的:
- 评估三个月里瓦洛克萨班治疗方案对近距离DVT的有效性.
- 为了使用QUT得分来比较凝块回归,比较里瓦洛克萨班和传统抗凝疗法.
主要方法:
- 对接受为期三个月的抗凝血药物的症状临近DVT患者的回顾性分析.
- 组A:里瓦洛克萨班单疗法 (n=42).
- 组B:历史队列 (n=60) 接受未分离的肝素或 fondaparinux 治疗,其次是维生素K 抗剂.
- 量化超声波血栓形成 (QUT) 评分用于测量治疗前后的凝块负担.
主要成果:
- 两组之间患者特征没有显著差异.
- 两组患者在治疗后的血清D-二聚物水平和QUT得分均显著改善.
- 与历史队列 (B组) 相比,里瓦洛克萨班组 (A组) 的QUT得分 (凝块减少) 的变化明显更大.
结论:
- 三个月的里瓦罗克萨班治疗对近端DVT有效.
- 与传统的抗凝治疗相比,利瓦罗克萨班在三个月的时间内表现出优异的血块回归,根据QUT评分进行评估.
- 这项研究支持使用里瓦洛克萨班治疗具有显著血栓分辨率的内脏病.
更多相关视频
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
519
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
519
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167


